<unk>  (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which<unk>  performed worse than the placebo, led to the trials being stopped.
Semagacestat
Dienogest
Gestonorone caproate
Triptorelin
Lumacaftor
Migalastat
Olestra
Ingenol mebutate